Clinical trials are voluntary placements for lung cancer patients to participate in new treatments. Most clinical trials include examinations, medication and follow up care for months or years after initial participation without cost to the individual. According to the Lung Cancer Alliance, these clinical trials pave the way for new drug options approved by the Food and Drug Administration and shape the future of cancer treatment and prognosis. However, most trials feature qualifications that patients must meet in order to participate.
Diagnosis
Before participation is allowed in a lung cancer clinical trial, an individual must be seen and diagnosed by a doctor specializing in cancer, also referred to as an oncologist. The oncologist has access to clinical trials throughout the country and will be informed of the latest exploratory drugs and openings available to his patients. Novartis explains that the fit for a particular clinical trial is generally decided by the oncologist and the type of cancer, noting that there are a number of qualifiers he must consider before making a referral.
Inclusion
Inclusion criteria is a prescribed set of rules governing the use and participation of patients in clinical trials. Medications, adjunctive treatment or placebos may be used that may not be recommended for certain types of cancer, growth or spread. Novartis explains that clinical trials set qualifiers for inclusion based on ideal circumstances for treatment effects to be seen. Based on laboratory research studies, clinical trials do not have sufficient research data to streamline them into regular cancer treatment. Therefore, they must limit complications that could potentially alter the accuracy of results or effectiveness.
Exclusion
Exclusion criteria is based on the same principles as inclusion criteria. Novartis explains that clinical trials may have preset values requiring age limits, gender qualifications, ethnic specifications or limitations on conflicting medical diagnoses and medications that are contraindicated or could be. This increases clinical trial safety and adherence to treatment and limits potential hazards to participants as well as the researchers involved.
